结果发现冷泉是氮损失热点,由多种微生物介导。该研究对理解海洋氮循环意义重大,推荐科研读者阅读。 中国自然资源部第三海洋研究所(Key Laboratory of Marine Genetic Resources, Third Institute of Oceanography, Ministry of Natural Resources)的研究人员 Qiuyun Jiang 等人在《Nature Communications》期刊上发表了题为 ...
为了攻克这些难题,来自多个国际研究机构的研究人员,包括 Saveetha Institute of Medical and Technical Sciences、JKK Munirajah College of Agricultural Science、AlMaarefa University 等,展开了关于 miR-21 在口腔癌进展中分子机制的研究。该研究成果发表在《World Journal of Surgical Oncology》上,为口腔癌的诊疗带来...
Human Applications CyTOF-ready, Flow Cytometry, Immunocytochemistry Label Janelia Fluor 549 Antibody Source Monoclonal Mouse IgG2AClone # 248621R Concentration Please see the vial label for concentration. If unlisted please contact technical services. ...
aAcad. Roumen Tsanev Institute of Molecular Biology[translate] afor get me not 为得到我没有[translate] aAcad. George Bonchev Street, Block 21[translate] aCappuccino taste 热奶咖啡口味[translate] aE-mdil: dodoff@obzor.bio21.bas.bg[translate]...
institute | NIBSC | Monobind | medkoo biosciences | medimabs | Mattek | macrocyclics | Lumafluor | lucerna | lifecore | leebio | lclabs | LC Laboratories | kerafast | iris-biotech | Insitus | innovagen | immusmol | ImmunoVision | Immunostep | immunodx | Immudex | iduron | Hyglos | ...
上海玉博生物科技有限公司主要致力于“Biolegend 代理(21) ”的生产销售。多年的“Biolegend 代理(21) ”生产与销售的经验,与各行业新老用户建立了稳定的合作关系,我公司经营的产品名称深受广大用户信赖。欢迎来电咨询或前来选购
Environmental Protection Agency (EPA), National Toxicology Program (NTP) headquartered at the National Institute of Environmental Health Sciences (NIEHS), National Center for Advancing Translational Sciences (NCATS), and Food and Drug Administration (FDA). https://tripod.nih.gov//tox21/pubdata/...
Bayer announced its 2023 cohort of Grants4Ag grant recipients who have been selected to research promising sustainability and biotechnology subjects in agriculture with support from Bayer.
原力转化研究院(Touchstone Translational Research Institute)是原力生命科学研发体系的核心板块,致力于成为全球基础科学发现、早期转化的领先合作平台。我们专注与全球顶尖的创新团队、高校、机构共同发现创新的、具有高价值临床优势潜力的创新免疫肿瘤新技术、新概念。凭借原力生命科学经验丰富的运营团队,领先的转化技术平台和...
SK Bioscience and Sanofi have started the process of submitting a phase 3 Investigational New Drug (IND) to the U.S. FDA for their jointly developed 21-valent pneumococcal protein conjugate vaccine candidate, GBP410 (Sanofi's project name: SP0202), to proceed to clinical trials, the Korean ...